This issue will feature a different Editor's message, as Neurology® Neuroimmunology & Neuroinflammation (N2) transitions to a new Editor, Dr. Josep Dalmau. Dr. Dalmau is a remarkable clinician-scientist-scholar who additionally carries the distinction of being transcontinental, holding positions at the University of Barcelona in Catalonia, Spain, and at the University of Pennsylvania. His distinctive achievement (among others) is to discover new diseases, beginning with meticulous, precise clinical observation and proceeding to identify causative autoantibodies often directed to neurotransmitter receptors. This work requires rigorous, encyclopedic knowledge of immunochemistry in addition to the tools and analytic techniques of clinical research. Dr. Dalmau has been an engaged Associate Editor during the N2 launch and is the ideal person to lead it forward.
The new Deputy Editor is equally distinguished: Dr. Scott Zamvil at the University of California, San Francisco, has a unique ability to deploy bench immunology for the deeper understanding of human disease, particularly in regard to multiple sclerosis (MS) and neuromyelitis optica (NMO).
In addition to their basic and clinical chops, Drs. Dalmau and Zamvil stand at the center of some of the most exciting areas of biomedicine: antibody-mediated neurologic disease and the human immunology around MS and NMO and their treatments.
My departure from N2 represents the incarnation of a bittersweet moment. For the past 10 years I have worked with the Neurology family, first at the flagship green journal and then with the astonishingly committed, energetic N2 team. Recently, when I was offered an opportunity to move with my lab group to Biogen Idec, one of the more challenging considerations was that it would no longer be appropriate to continue with N2. That was the bitter part. The sweetness comes from Dr. Dalmau's willingness to step into the Editor's “office” and Dr. Zamvil's agreeing to join him. In their capable hands, the journal will move forward to attain its full potential because of both the vibrant science in this field and their leadership of this effort. I look forward eagerly to watching future developments. Those of you who have started this journey with me have my enduring gratitude.
EDITOR-IN-CHIEF'S NOTE
Richard Ransohoff's departure is bittersweet for all of us on the Neurology team. Richard brought keen editorial, scientific, and clinical intelligence and insight, unparalleled knowledge of his fields, and an abiding loyalty to the green journals—first at Neurology, then at N2—to enrich their scope and breadth. N2 launched under his watch, and we could not have wished for a better leader in this effort. He has always offered me sound counsel, for which I am more grateful than I can adequately express. While we hope to keep him as a valued reviewer on N2's Editorial Board, other commitments permitting, we will miss his leadership. At the same time, we wish him only the best as he embarks on a new venture. Richard, we offer the entire team's thanks and congratulations on your new position.
To avoid potential conflict of interest related to Dr. Ransohoff's new affiliation with industry, Drs. Zamvil and Dalmau assisted with editorial duties in the creation of this issue.
—Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief, Neurology®
DISCLOSURE
Richard M. Ransohoff conducts research supported by the NIH, the National MS Society, the DOD, the Alzheimer's Association, the Guthy-Jackson Foundation, Williams Family Foundation for MS Research, ChemoCentryx, Lundbeck, Teva, Novartis, Genzyme, and Biogen-Idec. Dr. Ransohoff has received fees for preclinical consulting or honoraria for academic presentations from Amgen, Genentech, Roche, Novartis, Biogen-Idec, and Pfizer. He serves on scientific advisory, medical advisory, or safety monitoring boards for ChemoCentryx and Vertex. He receives an honorarium from the AAN as the Editor of Neurology: Neuroimmunology & Neuroinflammation. Robert A. Gross is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Since his appointment as Editor-in-Chief in 2009, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers' bureaus. He receives an honorarium from the AAN as Editor-in-Chief of Neurology. Go to Neurology.org/nn for full disclosures.
Footnotes
Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.
- © 2014 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
